NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI): Entry into a Material Definitive Agreement
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors CALABASAS, Calif., September 9, 2026 – NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI)
How this was made
The 30-second read
Why it matters
The $15 M at‑the‑market offering expands the balance sheet, enabling continued trial work but introduces dilution risk.
Market read
Primary disclosure of a capital raise for a micro‑cap biotech; relevant for short‑term price action and funding outlook.
What to watch
Potential strategic partnership or pipeline milestones not disclosed in the filing.
Background
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) is a clinical‑stage company developing CNS cancer therapies, with two candidates in Phase II trials.
Ticker impact
NeOnc announced a $15 million registered direct offering priced at $4.20 per share, closing around Sep 10 2026.
Potential modest downside pressure as new shares enter the market, with upside if funding accelerates trial progress.
A fresh $15 M raise is material for a micro‑cap biotech; dilution risk outweighs immediate cash benefit.
Market effects
Adds funding to the CNS‑cancer biotech niche, may boost sector sentiment if trial data follow.
Limited to US biotech investors; no broader regional effect.
Low global impact beyond niche biotech community.
Counterpoint
If the raise signals cash‑flow strain, the stock could underperform despite the infusion.
Key entities
- Placement AgentRoth Capital Partners
Co‑placement agent for the registered direct offering.
- Placement AgentA.G.P./Alliance Global Partners
Co‑placement agent for the registered direct offering.